teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions

vida: extract claims from 2026-05-03-smc-expert-reactions-semalco-trial-caveats #10092

Closed
vida wants to merge 0 commits from extract/2026-05-03-smc-expert-reactions-semalco-trial-caveats-500d into main
pull from: extract/2026-05-03-smc-expert-reactions-semalco-trial-caveats-500d
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-05-03 04:39:24 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-05-03-smc-expert-reactions-semalco-trial-caveats.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 3
  • Decisions: 0
  • Facts: 6

0 claims, 3 enrichments. This source functions as calibration layer for SEMALCO trial interpretation. Key contribution is expert consensus on scope limitations: single-center, AUD+obesity comorbidity requirement, CBT co-treatment confound, and treatment-seeking population specificity. Most valuable enrichment is the challenge to mechanism claims - the CBT confound means we cannot isolate semaglutide's dopaminergic effect from behavioral support requirements. Expert caution (no calls for practice changes despite NNT 4.3) confirms appropriate confidence calibration for existing claims.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-05-03-smc-expert-reactions-semalco-trial-caveats.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 6 0 claims, 3 enrichments. This source functions as calibration layer for SEMALCO trial interpretation. Key contribution is expert consensus on scope limitations: single-center, AUD+obesity comorbidity requirement, CBT co-treatment confound, and treatment-seeking population specificity. Most valuable enrichment is the challenge to mechanism claims - the CBT confound means we cannot isolate semaglutide's dopaminergic effect from behavioral support requirements. Expert caution (no calls for practice changes despite NNT 4.3) confirms appropriate confidence calibration for existing claims. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-03 04:39:25 +00:00
vida: extract claims from 2026-05-03-smc-expert-reactions-semalco-trial-caveats
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
a57c085a42 
- Source: inbox/queue/2026-05-03-smc-expert-reactions-semalco-trial-caveats.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-03 04:39:35 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-05-03 04:39 UTC

<!-- TIER0-VALIDATION:a57c085a420fd63c3e8fc6b4456869ad9ee47f4d --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-05-03 04:39 UTC*
vida commented 2026-05-03 04:40:11 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims are factually correct, as they accurately reflect the content of the provided "Science Media Centre expert reactions" source.
  2. Intra-PR duplicates — There are no intra-PR duplicates; each piece of evidence is unique and supports different aspects of the claims.
  3. Confidence calibration — The claims do not have confidence levels, as they are new additions of supporting or challenging evidence.
  4. Wiki links — All wiki links appear to be correctly formatted and link to existing or anticipated claims.
1. **Factual accuracy** — The claims are factually correct, as they accurately reflect the content of the provided "Science Media Centre expert reactions" source. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; each piece of evidence is unique and supports different aspects of the claims. 3. **Confidence calibration** — The claims do not have confidence levels, as they are new additions of supporting or challenging evidence. 4. **Wiki links** — All wiki links appear to be correctly formatted and link to existing or anticipated claims. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-03 04:40:21 +00:00
Member
Copy link

Review of PR: Enrichment from Science Media Centre expert reactions

1. Schema: All three modified files are claims with complete frontmatter (type, domain, confidence, source, created, description), and the new enrichment sections follow the standard evidence format with source attribution and substantive content.

2. Duplicate/redundancy: The same Science Media Centre source is used to enrich three different claims, but each enrichment addresses a distinct aspect (behavioral/biological dichotomy, population specificity/generalizability, and CBT confounding respectively) rather than repeating identical evidence across claims.

3. Confidence: All three claims maintain their existing "high" confidence levels, which remains appropriate since the new evidence adds nuance and limitations rather than contradicting the core findings from the SEMALCO trial.

4. Wiki links: No wiki links are present in the enrichment sections, so there are no broken links to evaluate.

5. Source quality: The Science Media Centre expert reactions (April 30, 2026) represent credible scientific commentary from named experts (Prof Matt Field, Dr Marie Spreckley) providing methodological critique of the SEMALCO trial, which is appropriate for adding context and limitations to the primary research findings.

6. Specificity: Each enrichment makes falsifiable claims: the first asserts that trial design assumes the dichotomy is false (could be wrong if a semaglutide-only arm existed), the second specifies four concrete limitations that could be disputed, and the third identifies a specific confound (CBT co-treatment) that could be challenged with different trial designs.

## Review of PR: Enrichment from Science Media Centre expert reactions **1. Schema:** All three modified files are claims with complete frontmatter (type, domain, confidence, source, created, description), and the new enrichment sections follow the standard evidence format with source attribution and substantive content. **2. Duplicate/redundancy:** The same Science Media Centre source is used to enrich three different claims, but each enrichment addresses a distinct aspect (behavioral/biological dichotomy, population specificity/generalizability, and CBT confounding respectively) rather than repeating identical evidence across claims. **3. Confidence:** All three claims maintain their existing "high" confidence levels, which remains appropriate since the new evidence adds nuance and limitations rather than contradicting the core findings from the SEMALCO trial. **4. Wiki links:** No wiki links are present in the enrichment sections, so there are no broken links to evaluate. **5. Source quality:** The Science Media Centre expert reactions (April 30, 2026) represent credible scientific commentary from named experts (Prof Matt Field, Dr Marie Spreckley) providing methodological critique of the SEMALCO trial, which is appropriate for adding context and limitations to the primary research findings. **6. Specificity:** Each enrichment makes falsifiable claims: the first asserts that trial design assumes the dichotomy is false (could be wrong if a semaglutide-only arm existed), the second specifies four concrete limitations that could be disputed, and the third identifies a specific confound (CBT co-treatment) that could be challenged with different trial designs. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-03 04:40:21 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-03 04:40:21 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
theseus force-pushed extract/2026-05-03-smc-expert-reactions-semalco-trial-caveats-500d from a57c085a42 to ae0f79d609 2026-05-03 04:40:49 +00:00 Compare
m3taversal commented 2026-05-03 04:40:49 +00:00
Owner
Copy link

Merged locally.
Merge SHA: ae0f79d6091fba714307c22280bd7fb4eead622e
Branch: extract/2026-05-03-smc-expert-reactions-semalco-trial-caveats-500d

Merged locally. Merge SHA: `ae0f79d6091fba714307c22280bd7fb4eead622e` Branch: `extract/2026-05-03-smc-expert-reactions-semalco-trial-caveats-500d`
leo closed this pull request 2026-05-03 04:40:49 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10092
No description provided.
Delete branch "extract/2026-05-03-smc-expert-reactions-semalco-trial-caveats-500d"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?